|Daily Range||$44.74 - $45.26|
|52-Week Range||$40.10 - $47.50|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||577,232|
|Current FY EPS||$2.06|
Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.
AbbVie probably isn't quaking in its boots with the FDA's decision to approve Antares' Otrexup. However, this could be great news for arthritis and psoriasis patients.